AI assistant
Sending…
Tempest Therapeutics, Inc. — Director's Dealing 2018
Dec 12, 2018
34632_dirs_2018-12-11_c9215fad-9104-475c-a7b2-697432a9a1eb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Millendo Therapeutics, Inc. (MLND)
CIK: 0001544227
Period of Report: 2018-12-07
Reporting Person: Arcudi III Louis J (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-12-07 | Employee Stock Option (right to buy) | $10.395 | A | 74400 | Acquired | 2028-12-06 | Common Stock (74400) | Direct |
Footnotes
F1: Twenty-five percent (25%) of the shares subject to the option shall vest on November 1, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
More from Tempest Therapeutics, Inc.
Regulatory Filings
2026
Jun 1
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 22
Regulatory Filings
2026
May 22
Interim / Quarterly Report
2026
May 14
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Apr 10
Regulatory Filings
2026
Apr 10
Regulatory Filings
2026
Mar 31